Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q2 2017 · 10-Q
Revenue$39.47K$39.47K−29.0% vs Q2 2016 Net Income-$260.42K-$260.42KN/M vs Q2 2016 EPS Diluted-$0.01-$0.01N/M vs Q2 2016 Gross Profit$20,077−45.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,398N/M Margins · derivedGross margin50.9%−15.3 pt vs Q2 2016
Operating margin-654.8%−397.1 pt vs Q2 2016
Net margin-659.7%−366.7 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 14, 2017 · 45 d after period end